Advarra has announced the acquisition of IntegReview IRB, an AAHRPP-accredited central IRB. As a market leader in early phase clinical research, the addition of IntegReview enables Advarra to continue its expansion of review solutions capabilities in North America.
"IntegReview and Advarra share a mission-driven passion for protecting clinical trial participants," said Gadi Saarony, CEO of Advarra. "Our aim is to benefit clinical trials and drug development through expanded subject matter expertise, technology-enabled efficiencies, and continuing commitment to ethics, quality, and service. We are excited to welcome more talent to enhance our combined capabilities and geographic footprint."
"We are excited to be a part of the Advarra family" said Lynn Meyer, founder and Managing Partner of IntegReview. "We were attracted to Advarra's extensive regulatory depth and their model of integrated IRB operations and focus on building client relationships and deep collaboration with the site community."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Advarra's expanded capabilities align to provide the research community and the biopharmaceutical industry with integrated, seamless solutions to advance healthcare in more meaningful ways. This also enables Advarra to extend its regulatory compliance expertise and further increase the greatest institutional reach of any independent IRB, serving well over 3,200 research institutions, hospital systems, and academic medical centers.